US · Healthcare · Biotechnology
EPS came in at 7.32 against a street estimate of 6.13 — a beat of 19.4%.
Analysts rate argenx NV ADR a buy (22 buy, 3 hold, 0 sell out of 25) with an average price target of $1,152.91.
| Fund | Stake |
|---|---|
| FMR Inc | 8.36% |
| T. Rowe Price Associates, Inc. | 4.28% |
| HHG PLC | 4.06% |
| Jupiter Topco LLC | 3.95% |
| Capital World Investors | 3.52% |
| Artisan Partners Limited Partnership | 2.41% |
| venBio Select Advisor LLC | 1.60% |
| Wellington Management Company LLP | 1.49% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • argenx SE filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of October 2026. • On October 8, 20 | 2026-10-08 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • argenx presented new clinical, long-term and real-world data for VYVGART, empasiprubart and adimanebart at the 2026 AANEM Annual M | 2026-09-29 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • argenx SE filed a Form 6-K with the U.S. Securities and Exchange Commission for August 2026. • The filing states that the com | 2026-08-27 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • argenx reported positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis. | 2026-08-17 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • argenx SE filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of August 2026. • The filing relate | 2026-08-03 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • argenx agreed to acquire Forte Biosciences for $77 per share in cash, implying a total equity value of approximately $2.2 billion. | 2026-07-27 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • argenx SE is a Netherlands-based biotechnology company listed on Nasdaq Global Select Market under ticker ARGX. • Fiscal year end | 2026-03-19 |
| Annual report FY2024 (20-F) | 2025-03-20 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for argenx NV ADR — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.